Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833022 · ClinicalTrials.gov registry record
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
A clinical trial of Sickle Cell Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 297
- Enrollment target
- 11
- Study locations
NCT05833022: Completed study of Sickle Cell Disease, sponsored by Novartis Pharmaceuticals.
NCT05833022 is a study of Sickle Cell Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 297 participants, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05833022, a study of Sickle Cell Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 297 participants
- Enrollment target
- 11
- Study locations
Study Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
Conditions Studied
Study Locations (11)
Ohio
- University Hospital at Cleveland Medical Center - Cleveland
- Ohio State University - Columbus
Alabama
- University of Alabama Birmingham - Birmingham
Delaware
- Cristiana Care - Wilmington
Florida
- All Children's Hospital - St. Petersburg
Maryland
- Johns Hopkins University - Baltimore
Missouri
- Washington University of St. Louis - St Louis
New Jersey
- Beth Israel Hospital - East Hanover
New York
- Montefiore - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2022-04-18 |
What the finished NCT05833022 record still lists
NCT05833022 is an observational study that tracks outcomes without assigning an intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05833022 lists 11 locations in 10 states (Ohio, Alabama, Delaware).
Frequently Asked Questions
What is clinical trial NCT05833022 about?
NCT05833022 is a clinical study titled "Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers". This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
What is the current status of trial NCT05833022?
This trial is currently completed. The enrollment target is 297 participants. The study started on 2021-07-30. Estimated completion is 2022-04-18.
What conditions does trial NCT05833022 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
Who is sponsoring clinical trial NCT05833022?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05833022 being conducted?
This trial has 11 study locations across Alabama, Delaware, Florida, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05833022's enrollment target sits among peer trials
297 21st of 213 higher than 193 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI